Routine therapeutic drug monitoring of tyrosine kinase inhibitors by HPLC–UV or LC–MS/MS methods
- 1 February 2016
- journal article
- review article
- Published by Elsevier BV in Drug Metabolism and Pharmacokinetics
- Vol. 31 (1), 12-20
- https://doi.org/10.1016/j.dmpk.2015.09.002
Abstract
No abstract availableKeywords
Funding Information
- Japan Society for the Promotion of Science (26460188, 26461414, 23590168)
This publication has 81 references indexed in Scilit:
- A validated assay for the simultaneous quantification of six tyrosine kinase inhibitors and two active metabolites in human serum using liquid chromatography coupled with tandem mass spectrometryJournal of Chromatography B, 2013
- Efficacy, safety, and pharmacokinetics of imatinib dose escalation to 800 mg/day in patients with advanced gastrointestinal stromal tumorsInvestigational New Drugs, 2013
- No clinical evidence for performing trough plasma and intracellular imatinib concentrations monitoring in patients with chronic myelogenous leukaemiaHematological Oncology, 2013
- A multicenter clinical study evaluating the confirmed complete molecular response rate in imatinib-treated patients with chronic phase chronic myeloid leukemia by using the international scale of real-time quantitative polymerase chain reactionHaematologica, 2013
- Pharmacokinetics of dasatinib for Philadelphia-positive acute lymphocytic leukemia with acquired T315I mutationJournal of Hematology & Oncology, 2012
- Plasma exposure of imatinib and its correlation with clinical response in the Tyrosine Kinase Inhibitor Optimization and Selectivity TrialHaematologica, 2012
- A validated LC–MS/MS assay for the simultaneous determination of the anti-leukemic agent dasatinib and two pharmacologically active metabolites in human plasma: Application to a clinical pharmacokinetic studyJournal of Pharmaceutical and Biomedical Analysis, 2012
- Chronic phase chronic myeloid leukemia patients with low OCT-1 activity randomized to high-dose imatinib achieve better responses and have lower failure rates than those randomized to standard-dose imatinibHaematologica, 2011
- Therapeutic Drug Monitoring of the new targeted anticancer agents imatinib, nilotinib, dasatinib, sunitinib, sorafenib and lapatinib by LC tandem mass spectrometryJournal of Chromatography B, 2009
- A high-performance liquid chromatography–mass spectrometry assay for quantitation of the tyrosine kinase inhibitor nilotinib in human plasma and serumJournal of Chromatography B, 2009